Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Alzheimer's disease drug market to increase from $4.3 billion to $13.3 billion in 2019: Report

Alzheimer's disease drug market to increase from $4.3 billion to $13.3 billion in 2019: Report

FINRA approves Curaxis' change of trading symbol to 'CURX'

FINRA approves Curaxis' change of trading symbol to 'CURX'

Protagen AG announces € 10.0 Million for second round of finance totaling

Protagen AG announces € 10.0 Million for second round of finance totaling

Study shows mild cognitive impairment affects men more than women

Study shows mild cognitive impairment affects men more than women

'Aspartame danger' myths

'Aspartame danger' myths

Study reveals factors linked to cognitive impairment in Type 2 diabetes

Study reveals factors linked to cognitive impairment in Type 2 diabetes

Researchers discover protein that stimulates production of beta-amyloid

Researchers discover protein that stimulates production of beta-amyloid

Benefit of delaying cognitive decline comes at the cost of more rapid dementia progression

Benefit of delaying cognitive decline comes at the cost of more rapid dementia progression

UTHealth professor to receive NIH Director's Pioneer Award

UTHealth professor to receive NIH Director's Pioneer Award

New research clinic in Edinburgh to improve outcomes for multiple sclerosis sufferers

New research clinic in Edinburgh to improve outcomes for multiple sclerosis sufferers

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list   for depression treatment

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

UBC researchers lead development of new 'toolbox of MiniPromoters' for gene research and therapy

UBC researchers lead development of new 'toolbox of MiniPromoters' for gene research and therapy

Brain lesion scan appearance shows increased multiple sclerosis activity during spring and summer

Brain lesion scan appearance shows increased multiple sclerosis activity during spring and summer

Elan Corporation offers to purchase Senior Fixed Rate Notes due 2013

Elan Corporation offers to purchase Senior Fixed Rate Notes due 2013

Homewatch CareGivers releases new guide related to dementia care

Homewatch CareGivers releases new guide related to dementia care

Latest achievements in brain research and treatment for mental disorders

Latest achievements in brain research and treatment for mental disorders

23rd ECNP Press conference on impact of circadian rhythms on human brain

23rd ECNP Press conference on impact of circadian rhythms on human brain

Most home care clients rely on informal care from spouse or child

Most home care clients rely on informal care from spouse or child

Mixed pathologies in brains of elderly account for memory loss and confusion

Mixed pathologies in brains of elderly account for memory loss and confusion

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.